The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 24, 2014
Filed:
Aug. 26, 2009
Andrew John Cooke, East Kilbride, GB;
David Jonathan Bennett, Edinburgh, GB;
Andrew Stanley Edwards, Campsie Glen, GB;
Andrew Laird Roughton, Port Hope, CA;
Irina Neagu, Belmont, MA (US);
Jui-hsiang Chan, West Windsor, NJ (US);
Koc-kan Ho, West Windsor, NJ (US);
Nasrin Ansari, Monmouth Junction, NJ (US);
Michelle Lee Morris, Lawrenceville, NJ (US);
Yajing Rong, Yardley, PA (US);
Michael Ohlmeyer, Plainsboro, NJ (US);
Andrew John Cooke, East Kilbride, GB;
David Jonathan Bennett, Edinburgh, GB;
Andrew Stanley Edwards, Campsie Glen, GB;
Andrew Laird Roughton, Port Hope, CA;
Irina Neagu, Belmont, MA (US);
Jui-Hsiang Chan, West Windsor, NJ (US);
Koc-Kan Ho, West Windsor, NJ (US);
Nasrin Ansari, Monmouth Junction, NJ (US);
Michelle Lee Morris, Lawrenceville, NJ (US);
Yajing Rong, Yardley, PA (US);
Michael Ohlmeyer, Plainsboro, NJ (US);
Merck Sharp & Dohme B.V., Oss, NL;
Pharmacopeia LLC., San Diego, CA (US);
Abstract
The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by hydroxy, cyano or halogen; Rrepresents 1 or 2 optional halogens; Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.